Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01239628
Other study ID # A-48-52120-152
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date December 2010
Est. completion date December 2015

Study information

Verified date March 2020
Source Ipsen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the protocol is to evaluate injection intervals and treatment modalities up to 3 years follow-up of botulinum toxin A (BoNT-A) in adult patients suffering from upper limb spasticity after stroke.


Recruitment information / eligibility

Status Terminated
Enrollment 45
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subject able to comply with the protocol

- Provision of written informed consent prior to collecting the data

- Male or female patients of 18 years or older

- Presenting with upper limb spasticity after stroke for which treatment with botulinum toxin A is indicated

Exclusion Criteria:

- The subject has already been included in this survey

- Patients who already received BoNT-A treatment for upper limb spasticity

- Patients with known intolerance for BoNT-A

- Subjects unable to comply with the protocol

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Belgium St- Augustinus Antwerpen
Belgium ZNA Middelheim Antwerpen
Belgium AZ St-Jan Brugge
Belgium RevalidatieZiekenhuis RevArte Edegem
Belgium AZ Sint Lucas Gent
Belgium Revalidatiecentrum St Ursula Herk-de-Stad
Belgium ZOL, Campus Sint Barbara Lanaken
Belgium Heilig Hart Ziekenhuis Lier
Belgium Hôpital Marie Curie Lodelinsart
Belgium CHU Leonardo da Vinci Montigny-le-Tilleul
Belgium CHPLT Peltzer Verviers

Sponsors (1)

Lead Sponsor Collaborator
Ipsen

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Documentation of the injection intervals 3 years
Primary Documentation of treatment modalities 3 years
Secondary Documentation of the main reason(s) for change in injection intervals 3 years
Secondary Documentation of the main reason(s) for dose change(s) 3 years
Secondary Documentation of the patient satisfaction with the treatment 3 years
Secondary Documentation of the physician satisfaction with the treatment 3 years